AquaMed Technologies, a subsidiary of HepaLife Technologies, has filed a 510(k) submission to the FDA seeking pre-market clearance for its silver based antimicrobial wound dressing, marketed under Hydress +Plus.
AquaMed Technologies manufactures custom hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics.
Upon approval, the Hydress +Plus silver based dressings are expected to be manufactured by AquaMed, which are currently marketed and sold through HepaLife’s Alliqua BioMedical (Alliqua) subsidiary.
Alliqua CEO Matt Harriton said that they believe that this product represents an important step forward in the field of advanced wound care, and one which has the potential to drive our business opportunities in the near term.
“The management team is committed to getting this product to market as quickly as possible while simultaneously developing strong distribution channels and marketing resources for its launch,” Harriton said.
“As the process for clearance takes place, we look forward to provide our shareholders with updates on this, as well as various other leading growth initiatives for our organization over the coming weeks and months.”